Condition: Metastatic Pancreatic Carcinoma · Sponsor: Zhejiang University
This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.
This description comes directly from the study's public registry record.
Tingbo Liang, MD · 86+19941463683 · liangtingbo@zju.edu.cn
Yiwen Chen, MD · 86+15088682641 · cherry0705@zju.edu.cn
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital of Zhejiang University Schlool of Medicine | Hangzhou, Zhejiang, China | Not Yet Recruiting |
| The First Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06770452